{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037924","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.050305+00:00","generated_at":"2026-06-12T07:05:02.945810+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytokinetics Q2 net loss widens to $128.6M; cuts 2023 spend by 15%, completes SEQUOIA-HCM enrollment","bullets":["Net loss of $128.6M ($1.34 loss per share) vs $19.8M ($0.23 loss) in Q2 2022.","Revenue fell to $0.9M from $89.0M, primarily due to no mavacamten royalty revenue in 2023.","Cash, equivalents and investments $592.6M at June 30, 2023.","Completed enrollment in SEQUOIA-HCM with 282 patients; topline results expected by end of 2023.","Revised 2023 operating expense guidance to $390-410M; net cash utilization ~$310-320M, saving ~15%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037924","json":"https://secwatch.observer/filing/0000950170-23-037924.json","markdown":"https://secwatch.observer/filing/0000950170-23-037924.md","text":"https://secwatch.observer/filing/0000950170-23-037924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/cytk-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:05:02.945810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02efed8316c0bf9b4f13b41b7487e0b9cfc94bc7","claim":"CYTOKINETICS INC updated its second quarter of 2023 guidance (reaffirmed).","evidence_excerpt":"On August 3, 2023, Cytokinetics, Incorporated (the \"Registrant\") announced its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4be6b02baa031c34a986fa72d68d9587315a9dbc","claim":"CYTOKINETICS INC updated its 2023 guidance (lowered).","evidence_excerpt":"The company today revised its financial guidance due to the reduction in expected operating expenses following the receipt of a CRL from the FDA regarding the New Drug Application for omecamtiv mecarbil and the discontinuation of COURAGE-ALS, the Phase 3 trial of reldesemtiv. The company anticipates operating expenses for 2023 will be in the range of $390 to $410 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}